The status of treatment study in angioimmunoblastic T-cell lymphoma
10.3760/cma.j.issn.1009-9921.2010.10.023
- VernacularTitle:血管免疫母细胞性T细胞淋巴瘤治疗研究进展
- Author:
Li FU
- Publication Type:Journal Article
- Keywords:
Lymphoma,T-cell;
Therapy;
Immunosuppression;
Transplantaion
- From:
Journal of Leukemia & Lymphoma
2010;19(10):634-636
- CountryChina
- Language:Chinese
-
Abstract:
Angioimmunoblastic T-cell lymphoma(AITL) is a subtype of peripheral T-cell lymphoma,clinically characterized with systemic symptoms and aggressive behaviours. To date, the standard approach for treating patients with AITL is still unknown. Combination chemotherapy regimens have failed to significantly improve prognosis and durably maintain the remission. Targeted drugs and immunomodulator agents could not conclude the role because of the small number of patients in these studies. High dose therapy with autologous stem cell transplantation and allogeneic hematologic stem cell transplantation are both comparatively efficient.High dose therapy with autologous stem cell transplantation has many risks, such as higher relapse rate and long-term secondary tumor. Owing to higher transplant related mortality , allogeneic hematologic stem cell transplantation will be further explored. This review presents the status of treatment study in AITL.
